Brand Name: Jublia
Generic Name: efinaconazole 10% topical solution
Medication Class: Triazole Antifungal
Similar Drugs: None, Jublia is the first topical triazole antifungal agent
Manufactured by: Valeant Pharmaceuticals International, Inc.
FDA Approval Date: June 9, 2014
What is Jublia and its mechanism of action?
Jublia is the first topical triazole antifungal agent developed for onychomycosis, a fungal infection of the nail (nail fungus). Onychomycosis is a common and destructive nail infection that occurs under the toenail or under the fingernail. Onychomycosis is a fungal infection caused by Trichophyton rubrum and Trichophyton mentagrophytes. Jublia works by blocking an enzyme that prevents the synthesis of ergosterol. Ergosterol is a chemical compound and an important part of fungal cell membranes. Fungi cannot survive without cell membranes. Jublia’s fungicidal action (fungi killing action) prevents the continued growth of fungi and heals the infection.
What does Jublia treat?
Jublia is FDA approved for the treatment of onychomycosis. Approximately 35 million people suffer from onychomycosis, the largest group affected are men between ages 50-70 years old.
The specific dermatophyte fungi that cause onychomycosis thrive in moist environments, such as swimming pools and showers and can invade the skin through cuts or separations between the toe and toenail. The infection starts as a small white or yellow spot underneath the nail and causes discoloration, thickening, or pain. If not treated, onychomycosis can cause permanent nail damage. There are around 85% of onychomycosis patients that are untreated.
Other treatments for onychomycosis include topical lacquers (e.g., ciclopirox), oral antifungal agents (e.g., terbinafine, itraconazole), and surgery.
What are interesting Jublia facts?
Next: Warnings, Side Effects, Efficacy Results